| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomarkers, Tumor | 14 | 2026 | 1580 | 1.940 |
Why?
|
| Proto-Oncogene Proteins B-raf | 8 | 2025 | 216 | 1.710 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 2 | 2022 | 17 | 1.390 |
Why?
|
| Melanoma | 6 | 2016 | 927 | 1.200 |
Why?
|
| Repressor Proteins | 5 | 2025 | 757 | 1.070 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2025 | 58 | 1.040 |
Why?
|
| Brain Abscess | 1 | 2024 | 54 | 0.820 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 151 | 0.820 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2024 | 157 | 0.800 |
Why?
|
| Thyroid Neoplasms | 3 | 2018 | 241 | 0.780 |
Why?
|
| Neutropenia | 1 | 2024 | 209 | 0.750 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2016 | 356 | 0.750 |
Why?
|
| Carcinoma, Papillary | 2 | 2013 | 91 | 0.750 |
Why?
|
| Mutation | 16 | 2026 | 6067 | 0.750 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 48 | 0.720 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 14 | 0.720 |
Why?
|
| Matrix Metalloproteinase 14 | 4 | 2010 | 10 | 0.710 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 36 | 0.630 |
Why?
|
| Sarcoma, Myeloid | 1 | 2019 | 10 | 0.620 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 289 | 0.600 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 92 | 0.600 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 175 | 0.590 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 112 | 0.590 |
Why?
|
| Skin Neoplasms | 3 | 2015 | 903 | 0.570 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2025 | 236 | 0.570 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 37 | 0.560 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 421 | 0.560 |
Why?
|
| Neoplasms | 5 | 2022 | 2975 | 0.550 |
Why?
|
| Extracellular Matrix | 2 | 2009 | 232 | 0.510 |
Why?
|
| Hepatoblastoma | 3 | 2026 | 204 | 0.500 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 1547 | 0.490 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2021 | 210 | 0.490 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 608 | 0.460 |
Why?
|
| Medical Oncology | 2 | 2014 | 241 | 0.460 |
Why?
|
| ErbB Receptors | 2 | 2016 | 285 | 0.450 |
Why?
|
| cdc42 GTP-Binding Protein | 3 | 2010 | 32 | 0.450 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 383 | 0.440 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 81 | 0.440 |
Why?
|
| Humans | 55 | 2026 | 130085 | 0.420 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2023 | 889 | 0.410 |
Why?
|
| Genetic Techniques | 1 | 2014 | 95 | 0.410 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 420 | 0.400 |
Why?
|
| Liver Neoplasms | 4 | 2026 | 1366 | 0.400 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2025 | 40 | 0.390 |
Why?
|
| Brain Neoplasms | 4 | 2025 | 1305 | 0.380 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 146 | 0.370 |
Why?
|
| Neoplasm Invasiveness | 4 | 2013 | 631 | 0.360 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2026 | 975 | 0.350 |
Why?
|
| Immunohistochemistry | 8 | 2017 | 1592 | 0.350 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 223 | 0.340 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 314 | 0.330 |
Why?
|
| Carcinoma | 1 | 2013 | 283 | 0.330 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2024 | 598 | 0.320 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 777 | 0.320 |
Why?
|
| Child | 18 | 2026 | 26174 | 0.310 |
Why?
|
| Transcription Factors | 3 | 2026 | 2400 | 0.290 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2025 | 229 | 0.280 |
Why?
|
| Genetic Testing | 2 | 2019 | 1103 | 0.280 |
Why?
|
| DNA-Binding Proteins | 4 | 2026 | 1931 | 0.270 |
Why?
|
| Genomics | 2 | 2021 | 1617 | 0.260 |
Why?
|
| Carcinoma, Ductal | 1 | 2026 | 14 | 0.240 |
Why?
|
| Transcriptome | 1 | 2013 | 1097 | 0.240 |
Why?
|
| Parotid Neoplasms | 1 | 2026 | 21 | 0.240 |
Why?
|
| GTP-Binding Proteins | 1 | 2006 | 156 | 0.240 |
Why?
|
| Signal Transduction | 4 | 2015 | 4645 | 0.230 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2026 | 70 | 0.230 |
Why?
|
| Adolescent | 13 | 2026 | 20800 | 0.230 |
Why?
|
| Translocation, Genetic | 2 | 2025 | 344 | 0.230 |
Why?
|
| B7-H1 Antigen | 2 | 2026 | 133 | 0.230 |
Why?
|
| Quality Control | 2 | 2016 | 116 | 0.220 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2024 | 21 | 0.210 |
Why?
|
| Female | 23 | 2026 | 70246 | 0.210 |
Why?
|
| Collagen | 4 | 2010 | 274 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2015 | 2008 | 0.210 |
Why?
|
| Skull | 1 | 2025 | 148 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2025 | 352 | 0.200 |
Why?
|
| Bone Marrow | 1 | 2025 | 317 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 165 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 4 | 2022 | 1690 | 0.200 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 2076 | 0.200 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 154 | 0.190 |
Why?
|
| Lipids | 1 | 2006 | 566 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 719 | 0.190 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 46 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 130 | 0.190 |
Why?
|
| Endonucleases | 2 | 2013 | 53 | 0.190 |
Why?
|
| Infant | 6 | 2026 | 13269 | 0.180 |
Why?
|
| Fibroma | 1 | 2022 | 29 | 0.180 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 968 | 0.180 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 280 | 0.180 |
Why?
|
| Neoplasm Proteins | 1 | 2026 | 679 | 0.180 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 16 | 0.180 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 76 | 0.180 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 145 | 0.180 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 47 | 0.170 |
Why?
|
| Male | 19 | 2026 | 64386 | 0.170 |
Why?
|
| Glioblastoma | 1 | 2025 | 372 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 143 | 0.170 |
Why?
|
| Membrane Proteins | 3 | 2026 | 1589 | 0.170 |
Why?
|
| Ribonuclease III | 1 | 2022 | 100 | 0.170 |
Why?
|
| Ligands | 1 | 2022 | 480 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 124 | 0.170 |
Why?
|
| Cell Movement | 3 | 2009 | 873 | 0.170 |
Why?
|
| DNA Copy Number Variations | 2 | 2026 | 1025 | 0.160 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 160 | 0.160 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 78 | 0.160 |
Why?
|
| Cyclin B | 1 | 2019 | 21 | 0.150 |
Why?
|
| Sarcoma | 1 | 2022 | 218 | 0.150 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 81 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 145 | 0.150 |
Why?
|
| Ependymoma | 1 | 2021 | 137 | 0.150 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2019 | 20 | 0.150 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 19 | 0.150 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 28 | 0.150 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2019 | 15 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 1 | 2022 | 639 | 0.150 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2019 | 11 | 0.150 |
Why?
|
| Azacitidine | 1 | 2019 | 51 | 0.150 |
Why?
|
| Pyridazines | 1 | 2019 | 49 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1265 | 0.150 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2018 | 5 | 0.140 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 85 | 0.140 |
Why?
|
| Hypercalcemia | 1 | 2018 | 41 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 306 | 0.140 |
Why?
|
| Granulosa Cell Tumor | 1 | 2018 | 38 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2021 | 355 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 37 | 0.140 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 123 | 0.140 |
Why?
|
| Imidazoles | 1 | 2019 | 219 | 0.140 |
Why?
|
| Radiation Exposure | 1 | 2018 | 45 | 0.140 |
Why?
|
| Codon, Nonsense | 1 | 2018 | 138 | 0.130 |
Why?
|
| Pyrimidines | 1 | 2021 | 454 | 0.130 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 322 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 194 | 0.130 |
Why?
|
| Child, Preschool | 6 | 2026 | 15005 | 0.130 |
Why?
|
| Stomach Neoplasms | 2 | 2013 | 572 | 0.130 |
Why?
|
| Leukemia | 1 | 2020 | 375 | 0.130 |
Why?
|
| DNA Helicases | 1 | 2018 | 234 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 742 | 0.130 |
Why?
|
| Thrombocytosis | 1 | 2017 | 34 | 0.120 |
Why?
|
| Prognosis | 6 | 2019 | 4848 | 0.120 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2016 | 3 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 102 | 0.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 870 | 0.120 |
Why?
|
| Survivors | 1 | 2018 | 345 | 0.120 |
Why?
|
| Heterozygote | 1 | 2018 | 721 | 0.120 |
Why?
|
| Ovary | 1 | 2018 | 345 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 35 | 0.120 |
Why?
|
| Endothelial Cells | 2 | 2010 | 520 | 0.120 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 50 | 0.120 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 40 | 0.120 |
Why?
|
| Limit of Detection | 1 | 2016 | 72 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 735 | 0.120 |
Why?
|
| Calreticulin | 1 | 2015 | 23 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2019 | 376 | 0.120 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 22 | 0.120 |
Why?
|
| Apoptosis | 1 | 2022 | 1826 | 0.120 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Oxo-Acid-Lyases | 1 | 2015 | 5 | 0.110 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2015 | 16 | 0.110 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2015 | 46 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 108 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2015 | 91 | 0.110 |
Why?
|
| DNA Primers | 1 | 2014 | 600 | 0.100 |
Why?
|
| Lipoma | 1 | 2013 | 24 | 0.100 |
Why?
|
| Thymidylate Synthase | 1 | 2013 | 20 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 612 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 141 | 0.100 |
Why?
|
| Models, Biological | 2 | 2009 | 1375 | 0.100 |
Why?
|
| Young Adult | 5 | 2025 | 9981 | 0.100 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 1 | 0.090 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2012 | 11 | 0.090 |
Why?
|
| Middle Aged | 8 | 2025 | 28314 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1208 | 0.090 |
Why?
|
| Specialties, Surgical | 1 | 2013 | 90 | 0.090 |
Why?
|
| Adult | 8 | 2025 | 31011 | 0.090 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2012 | 23 | 0.090 |
Why?
|
| Aged | 7 | 2016 | 20821 | 0.090 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 103 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 3713 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1800 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 525 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2891 | 0.080 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 125 | 0.080 |
Why?
|
| Exons | 1 | 2013 | 759 | 0.080 |
Why?
|
| Base Sequence | 1 | 2014 | 2729 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 6765 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2014 | 920 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 484 | 0.080 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2009 | 36 | 0.070 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2009 | 99 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2009 | 91 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 196 | 0.070 |
Why?
|
| Recurrence | 2 | 2025 | 1475 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 662 | 0.070 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2006 | 3 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 369 | 0.060 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2006 | 10 | 0.060 |
Why?
|
| Sphingosine | 1 | 2006 | 23 | 0.060 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 368 | 0.060 |
Why?
|
| Lysophospholipids | 1 | 2006 | 45 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 62 | 0.060 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2006 | 65 | 0.060 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2026 | 65 | 0.060 |
Why?
|
| Bone Resorption | 1 | 2025 | 52 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2026 | 2290 | 0.060 |
Why?
|
| Receptors, Purinergic P2Y | 1 | 2025 | 6 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 975 | 0.060 |
Why?
|
| Receptors, Cytokine | 1 | 2025 | 65 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2026 | 207 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1212 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1800 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 345 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1874 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 77 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 94 | 0.050 |
Why?
|
| Phenotype | 2 | 2026 | 4456 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 980 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2026 | 3404 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 425 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 57 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 902 | 0.050 |
Why?
|
| Receptor, trkB | 1 | 2021 | 22 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2022 | 147 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2022 | 103 | 0.040 |
Why?
|
| Pancreas | 1 | 2022 | 218 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2026 | 1076 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 820 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1069 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2010 | 2885 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 44 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 269 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 573 | 0.040 |
Why?
|
| Mice | 3 | 2025 | 18160 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 406 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2019 | 77 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 1393 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2018 | 3 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2018 | 4 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 39 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2019 | 156 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 306 | 0.040 |
Why?
|
| Germ Cells | 1 | 2019 | 201 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2017 | 45 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2026 | 3677 | 0.030 |
Why?
|
| Time Factors | 1 | 2006 | 6165 | 0.030 |
Why?
|
| Pathology, Surgical | 1 | 2016 | 17 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 653 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 4691 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 316 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 70 | 0.030 |
Why?
|
| Polyps | 1 | 2016 | 38 | 0.030 |
Why?
|
| Acetoacetates | 1 | 2015 | 14 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 5034 | 0.030 |
Why?
|
| Animals | 3 | 2025 | 33660 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2015 | 55 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1662 | 0.030 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2013 | 8 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 404 | 0.020 |
Why?
|
| Endometrium | 1 | 2016 | 286 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 823 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 272 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1325 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 242 | 0.020 |
Why?
|
| Uterus | 1 | 2016 | 540 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4639 | 0.020 |
Why?
|
| Risk Factors | 1 | 2026 | 10960 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 292 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 928 | 0.020 |
Why?
|
| Microscopy, Video | 1 | 2009 | 15 | 0.020 |
Why?
|
| Integrin alpha Chains | 1 | 2009 | 15 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2009 | 36 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2009 | 33 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 551 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 2588 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 59 | 0.020 |
Why?
|
| Laminin | 1 | 2009 | 66 | 0.020 |
Why?
|
| Cues | 1 | 2009 | 80 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2009 | 37 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 222 | 0.020 |
Why?
|
| Antibodies | 1 | 2010 | 316 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 308 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 3026 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 287 | 0.020 |
Why?
|
| Cell Communication | 1 | 2009 | 188 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 287 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2009 | 340 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2009 | 409 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5167 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 2687 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 613 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 705 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 17541 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 6402 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3114 | 0.010 |
Why?
|